Antipsychotic use and 28-day mortality in patients hospitalized with COVID-19 : A multicenter observational retrospective study
Copyright © 2023. Published by Elsevier B.V..
Prior research has yielded conflicting results about the potential influence of antipsychotics in patients with COVID-19. In this multicenter retrospective study, we examined the association of antipsychotic use at admission with 28-day all-cause mortality in a sample of 59,021 adult patients hospitalized with COVID-19 from January 2020 to November 2021. In a 1:1 ratio matched analytic sample (N=1,454) accounting for age, sex, hospital, hospitalization period, the Elixhauser Comorbidity Index, other psychotropic medications, medications prescribed according to compassionate use or as part of a clinical trial, current diagnoses of psychiatric disorders, and clinical and biological markers of COVID-19 severity, antipsychotic use was not associated with 28-day mortality [23.5% (N=727) versus 18.6% (N=727); OR=1.16; 95%CI=0.89-1.51; p=0.280]. This association remained non-significant in exploratory analyses across all classes of antipsychotics and individual molecules, except for typical antipsychotics and loxapine, which were significantly linked to increased 28-day mortality, associations likely due to residual indication bias. Contrariwise, antipsychotics prescribed at daily doses higher than 200 mg of chlorpromazine-equivalents might be associated with reduced 28-day mortality when compared to patients not taking antipsychotics in the matched analytic sample [10.4% (N=154) versus 18.6% (N=727); AOR=0.56; 95%CI=0.31-0.96; p=0.040]. These results suggest that antipsychotic use, when prescribed at usual doses, are not be associated with 28-day mortality in patients hospitalized with COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
|---|---|
| Enthalten in: |
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology - 75(2023) vom: 02. Okt., Seite 93-104 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sánchez-Rico, Marina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acid sphingomyelinase |
|---|
| Anmerkungen: |
Date Revised 01.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.euroneuro.2023.06.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362108781 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362108781 | ||
| 003 | DE-627 | ||
| 005 | 20231226090539.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.euroneuro.2023.06.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1206.xml |
| 035 | |a (DE-627)NLM362108781 | ||
| 035 | |a (NLM)37713738 | ||
| 035 | |a (PII)S0924-977X(23)00124-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sánchez-Rico, Marina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antipsychotic use and 28-day mortality in patients hospitalized with COVID-19 |b A multicenter observational retrospective study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023. Published by Elsevier B.V. | ||
| 520 | |a Prior research has yielded conflicting results about the potential influence of antipsychotics in patients with COVID-19. In this multicenter retrospective study, we examined the association of antipsychotic use at admission with 28-day all-cause mortality in a sample of 59,021 adult patients hospitalized with COVID-19 from January 2020 to November 2021. In a 1:1 ratio matched analytic sample (N=1,454) accounting for age, sex, hospital, hospitalization period, the Elixhauser Comorbidity Index, other psychotropic medications, medications prescribed according to compassionate use or as part of a clinical trial, current diagnoses of psychiatric disorders, and clinical and biological markers of COVID-19 severity, antipsychotic use was not associated with 28-day mortality [23.5% (N=727) versus 18.6% (N=727); OR=1.16; 95%CI=0.89-1.51; p=0.280]. This association remained non-significant in exploratory analyses across all classes of antipsychotics and individual molecules, except for typical antipsychotics and loxapine, which were significantly linked to increased 28-day mortality, associations likely due to residual indication bias. Contrariwise, antipsychotics prescribed at daily doses higher than 200 mg of chlorpromazine-equivalents might be associated with reduced 28-day mortality when compared to patients not taking antipsychotics in the matched analytic sample [10.4% (N=154) versus 18.6% (N=727); AOR=0.56; 95%CI=0.31-0.96; p=0.040]. These results suggest that antipsychotic use, when prescribed at usual doses, are not be associated with 28-day mortality in patients hospitalized with COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acid sphingomyelinase | |
| 650 | 4 | |a Antipsychotic | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a FIASMA | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Edán-Sánchez, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Olfson, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Alvarado, Jesús M |e verfasserin |4 aut | |
| 700 | 1 | |a Airagnes, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Rezaei, Katayoun |e verfasserin |4 aut | |
| 700 | 1 | |a Delcuze, Aude |e verfasserin |4 aut | |
| 700 | 1 | |a Peyre, Hugo |e verfasserin |4 aut | |
| 700 | 1 | |a Limosin, Frédéric |e verfasserin |4 aut | |
| 700 | 1 | |a Hoertel, Nicolas |e verfasserin |4 aut | |
| 700 | 0 | |a AP-HP / Université Paris Cité / INSERM COVID-19 research collaboration, AP-HP COVID CDR Initiative, and “Entrepôt de Données de Santé” AP-HP Consortium |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology |d 1997 |g 75(2023) vom: 02. Okt., Seite 93-104 |w (DE-627)NLM013028618 |x 1873-7862 |7 nnns |
| 773 | 1 | 8 | |g volume:75 |g year:2023 |g day:02 |g month:10 |g pages:93-104 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.euroneuro.2023.06.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 75 |j 2023 |b 02 |c 10 |h 93-104 | ||